Orphan drugs and where to launch them: The keys to Europe’s forgotten territories
Pharmaceutical Technology
JULY 14, 2022
Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.
Let's personalize your content